NIKKEI 225
38,202.37 -632.73 (-1.63%) HANG SENG
18,313.86 -165.51 (-0.90%) CRUDE OIL
78.90 +0.52 (+0.66%) GOLD FUTURES
2,325.60 +1.40 (+0.06%) DOW
38,970.61 +86.35 (+0.22%) Bitcoin GBP
49,820.47 -1,035.05 (-2.04%)
Celcuity Inc. (CELC)
| Previous close | 17.70 |
| Open | 17.74 |
| Bid | 17.62 x 100 |
| Ask | 17.73 x 100 |
| Day's range | 17.50 - 17.79 |
| 52-week range | 8.39 - 22.19 |
| Volume | |
| Avg. volume | 243,057 |
| Market cap | 536.888M |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call
MINNEAPOLIS, May 08, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the first quarter 2024 after the market closes on Wednesday, May 15, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. Webcast and Conference Call Information To partici
- GlobeNewswire
Celcuity To Present at Upcoming Needham and Stifel Investor Conferences
MINNEAPOLIS, April 04, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences: A fireside chat at the 23rd Annual Needham Virtual Healthcare Conference at 2:15 p.m. ET on Thursday, April 11, 2024. A live webcast w
- GlobeNewswire
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data demonstrating the superior therapeutic effects of gedatolisib compared to other PI3K/AKT/mTOR inhibitors at the 2023 SABCSRaised $65 million from the sale of equity; expect cash, cash equivalents, investments and available funds under our debt facility, to fund current operational activities into firs
